Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study (ENDO-RESIST)
研究概览
地位
条件
详细说明
Endocrine therapies have been associated with an overall survival benefit in breast cancer and are the preferred initial treatment approach in patients with ER+, HER2- metastatic breast cancer. Unfortunately, resistance to endocrine therapies eventually develops in the metastatic setting and metastatic breast cancer remains an incurable disease. Endocrine resistance may develop as a result of alterations in estrogen signaling and metabolism pathways, which may be modulated by gut bacteria. In addition, genomic profiling of archival tissues and circulating tumor DNA (ctDNA) in ER+ breast cancer has identified multiple somatic molecular alterations that may mediate response to endocrine therapies.
This study is designed to identify markers of endocrine resistance in ctDNA and the gut microbiome in patients with ER+ HER2- metastatic breast cancer.
研究类型
注册 (预期的)
联系人和位置
学习联系方式
- 姓名:Rossanna C. Pezo, MD/PhD
- 电话号码:416-480-4757
- 邮箱:rossanna.pezo@sunnybrook.ca
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M4N 3M5
- 招聘中
- Sunnybrook Health Sciences Centre
-
接触:
- Rossanna C. Pezo, MD/PhD
- 电话号码:416-480-4757
- 邮箱:rossanna.pezo@sunnybrook.ca
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Sign written and voluntary informed consent
- Histological confirmation of advanced ER positive and HER2 negative breast cancer.
- Adult patients at least 18 years of age
- ECOG performance status equal to 0 or 1
- Able to provide written informed consent
- Must be willing to provide blood for ctDNA analysis on study enrollment and at specified study time points
- Must be willing and able to perform stool sample collection
- Patients must be suitable, as per their treating physician, for initiation of first line endocrine therapy with an aromatase inhibitor and a CDK 4/6 inhibitor for metastatic disease
Exclusion Criteria:
- Prior treatment with CDK 4/6 inhibitors in the neoadjuvant or adjuvant setting
- Use of targeted therapies other than endocrine therapies alone in the neoadjuvant or adjuvant setting
- Relapse on prior endocrine therapy or within 6 months of discontinuation of prior adjuvant endocrine therapy
- History of inflammatory bowel disease, chronic diarrhea or malabsorption syndromes and significant prior bowel resection as judged by the study investigator
- Use of immunosuppressants including steroids within the previous 4 weeks of planned Cycle 1 Day 1 treatment
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to treatment failure
大体时间:12 months
|
Time from first treatment on study (standard of care aromatase inhibitor and a CDK 4/6 inhibitor) until the date of treatment discontinuation
|
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Correlation between specific mutations in ctDNA and in archival tissue samples (where available from prior testing) with time to treatment failure
大体时间:12 months
|
Identification of mutations in archival tissue samples (where available from prior testing) and sequencing of ctDNA using next generation sequencing panel
|
12 months
|
|
Diversity and composition of the gut microbiome in patients with ER+ HER2- metastatic breast cancer
大体时间:12 months
|
Analysis of the gut microbiome via 16S rRNA sequencing and metagenomic sequencing of fecal samples at baseline and at development of progressive disease
|
12 months
|
|
Dietary factors and composition of the gut microbiome
大体时间:14 days
|
Assessment of food intake via dietary questionnaire and correlation with diversity and composition of the gut microbiome
|
14 days
|
|
Overall survival
大体时间:2 years
|
Time from start of treatment until death
|
2 years
|
合作者和调查者
调查人员
- 首席研究员:Rossanna C. Pezo, MD/PhD、Sunnybrook Health Sciences Centre
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.